Two Novel Monovalent Serotype-2 Poliovirus Vaccines

In a phase I study, two novel live-attenuated type-2 poliovirus vaccines were safe and immunogenic in previously IPV-vaccinated adults.

Polio eradication requires withdrawing live-attenuated oral poliovirus vaccines (OPV) because of the potential for vaccine-derived polioviruses (VDPV) to revert to neurovirulence, causing paralysis and outbreaks. Yet halting vaccine-associated polio outbreaks requires use of live vaccine because inactivated poliovirus vaccine (IPV) does not generate mucosal immunity, needed to stop transmission.

Two novel OPV serotype-2 (OPV2) candidates were created by genetic modification to improve stability. To assess these vaccines' immunogenicity, safety, tolerability, fecal shedding, and potential for reversion to neurovirulence, investigators conducted a phase I trial, administering either of the single-dose vaccines to 30 healthy, previously IPV-vac…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Two Novel Monovalent Serotype-2 Poliovirus Vaccines

Topics

Reviewing Author